Mumbai: Cupid Limited held its 32nd Annual General Meeting today, where Chairman and Managing Director Mr. Aditya Kumar Halwasiya addressed shareholders with a confident outlook for the future. Reflecting on the company’s robust performance in FY25, he unveiled an ambitious roadmap for FY26, positioning Cupid for its most successful quarter yet.
Aditya Kumar Halwasiya emphasized that Q2 FY26 is expected to be the best quarter in Cupid’s history. This optimistic forecast is backed by a surge in new product launches, rapid growth in the FMCG vertical, and a strong pipeline of institutional orders. These developments are set to drive record-breaking performance while laying the groundwork for sustainable expansion across all business lines.
Cupid’s FY25 results showcased impressive financial and operational achievements. The company reported a total income of ₹203.18 crore and a net profit of ₹40.89 crore, reflecting a healthy net margin exceeding 22%. Its net worth crossed ₹342 crore, and its global footprint expanded with products sold in over 110 countries. Notably, the B2C FMCG segment delivered ₹50+ crore in revenue within its first year, reaching 1.2 lakh retail outlets across India. Additionally, the diagnostics division marked a milestone by turning profitable, with 15 test kits and growing international registrations.
Strategically, Cupid is gearing up for major capacity expansion with the commissioning of its Palava Plant in Maharashtra during H2 FY26. This facility will enhance manufacturing capabilities across condoms, diagnostics, and FMCG products. The company also announced the establishment of a new UAE subsidiary to lead acquisitions and strengthen its presence in the MENA region. On the regulatory front, Cupid secured UNFPA prequalification for its Brown Caramel Female Condom and is actively pursuing CE and WHO certifications for its diagnostics kits.
Commenting on the development, Aditya Kumar Halwasiya said, “Cupid is no longer just a contraceptive company, it is transforming into a consumer wellness and health-tech leader, with a clear focus on sustainable growth, global expansion, and innovation while ensuring personal care and preventive healthcare are accessible to all. We are entering a defining phase in our journey and, with new product launches, strong momentum in our FMCG vertical, and a robust pipeline of institutional orders, Q2 FY26 is gearing up to be the strongest quarter in our history. This reflects our strategic clarity, disciplined execution, and the strength of our evolving multi-category, multi-geography model. With robust financial resources, continuous product innovation, and a sharper go-to-market strategy, we are confident of sustaining growth momentum while creating lasting value for our shareholders.”
Looking ahead to FY26, Cupid aims to cross ₹100 crore in FMCG revenues and expand its retail reach to 1.8 lakh outlets across India. The company plans to scale global diagnostics exports, commission the Palava Plant as a next-generation manufacturing hub, and launch a range of new products including flavoured and dotted condoms, petroleum jelly mini-packs, and premium women’s deodorants.
With a clear strategic vision and strong execution capabilities, Cupid Limited is poised to redefine its growth trajectory and reinforce its leadership in the sexual wellness, diagnostics, and FMCG sectors.
